BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Advocacy groups react after Mattel introduces 1st Barbie doll with autism- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms
- Defence chiefs of Thailand and Cambodia to discuss ceasefire
- Most loved Seared Chicken: Which Chain Rules?
- Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- Help Your Efficiency with These Work area Updates
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- Students were skipping my astrophysics class to play video games – so I turned the class itself into a video game
